BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 33306954)

  • 1. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.
    Dong J; Cross RW; Doyle MP; Kose N; Mousa JJ; Annand EJ; Borisevich V; Agans KN; Sutton R; Nargi R; Majedi M; Fenton KA; Reichard W; Bombardi RG; Geisbert TW; Crowe JE
    Cell; 2020 Dec; 183(6):1536-1550.e17. PubMed ID: 33306954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme-Linked Immunosorbent Assay Using Henipavirus-Receptor EphrinB2 and Monoclonal Antibodies for Detecting Nipah and Hendra Viruses.
    Zhu W; Smith G; Pickering B; Banadyga L; Yang M
    Viruses; 2024 May; 16(5):. PubMed ID: 38793674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems.
    Bossart KN; McEachern JA; Hickey AC; Choudhry V; Dimitrov DS; Eaton BT; Wang LF
    J Virol Methods; 2007 Jun; 142(1-2):29-40. PubMed ID: 17292974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.
    Zhu Z; Dimitrov AS; Bossart KN; Crameri G; Bishop KA; Choudhry V; Mungall BA; Feng YR; Choudhary A; Zhang MY; Feng Y; Wang LF; Xiao X; Eaton BT; Broder CC; Dimitrov DS
    J Virol; 2006 Jan; 80(2):891-9. PubMed ID: 16378991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein.
    Doyle MP; Kose N; Borisevich V; Binshtein E; Amaya M; Nagel M; Annand EJ; Armstrong E; Bombardi R; Dong J; Schey KL; Broder CC; Zeitlin L; Kuang EA; Bornholdt ZA; West BR; Geisbert TW; Cross RW; Crowe JE
    Cell Rep; 2021 Aug; 36(9):109628. PubMed ID: 34469726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice.
    Li Y; Li R; Wang M; Liu Y; Yin Y; Zai X; Song X; Chen Y; Xu J; Chen W
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32340278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-guided mutagenesis of Henipavirus receptor-binding proteins reveals molecular determinants of receptor usage and antibody-binding epitopes.
    Oguntuyo KY; Haas GD; Azarm KD; Stevens CS; Brambilla L; Kowdle SS; Avanzato VA; Pryce R; Freiberg AN; Bowden TA; Lee B
    J Virol; 2024 Mar; 98(3):e0183823. PubMed ID: 38426726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines to Emerging Viruses: Nipah and Hendra.
    Amaya M; Broder CC
    Annu Rev Virol; 2020 Sep; 7(1):447-473. PubMed ID: 32991264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.
    Zhu Z; Bossart KN; Bishop KA; Crameri G; Dimitrov AS; McEachern JA; Feng Y; Middleton D; Wang LF; Broder CC; Dimitrov DS
    J Infect Dis; 2008 Mar; 197(6):846-53. PubMed ID: 18271743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody.
    Xu K; Rockx B; Xie Y; DeBuysscher BL; Fusco DL; Zhu Z; Chan YP; Xu Y; Luu T; Cer RZ; Feldmann H; Mokashi V; Dimitrov DS; Bishop-Lilly KA; Broder CC; Nikolov DB
    PLoS Pathog; 2013; 9(10):e1003684. PubMed ID: 24130486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant.
    Wang Z; Dang HV; Amaya M; Xu Y; Yin R; Yan L; Hickey AC; Annand EJ; Horsburgh BA; Reid PA; Smith I; Eden JS; Xu K; Broder CC; Veesler D
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122769119. PubMed ID: 35617431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.
    Bossart KN; Crameri G; Dimitrov AS; Mungall BA; Feng YR; Patch JR; Choudhary A; Wang LF; Eaton BT; Broder CC
    J Virol; 2005 Jun; 79(11):6690-702. PubMed ID: 15890907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Nipah and Hendra Viruses Using Recombinant Human Ephrin B2 Capture Virus in Immunoassays.
    Yang M; Zhu W; Truong T; Pickering B; Babiuk S; Kobasa D; Banadyga L
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins.
    Dang HV; Cross RW; Borisevich V; Bornholdt ZA; West BR; Chan YP; Mire CE; Da Silva SC; Dimitrov AS; Yan L; Amaya M; Navaratnarajah CK; Zeitlin L; Geisbert TW; Broder CC; Veesler D
    Nat Struct Mol Biol; 2021 May; 28(5):426-434. PubMed ID: 33927387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection.
    Mire CE; Chan YP; Borisevich V; Cross RW; Yan L; Agans KN; Dang HV; Veesler D; Fenton KA; Geisbert TW; Broder CC
    J Infect Dis; 2020 May; 221(Suppl 4):S471-S479. PubMed ID: 31686101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prefusion stabilization of the Hendra and Langya virus F proteins.
    Byrne PO; Blade EG; Fisher BE; Ambrozak DR; Ramamohan AR; Graham BS; Loomis RJ; McLellan JS
    J Virol; 2024 Feb; 98(2):e0137223. PubMed ID: 38214525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.
    Guillaume V; Wong KT; Looi RY; Georges-Courbot MC; Barrot L; Buckland R; Wild TF; Horvat B
    Virology; 2009 May; 387(2):459-65. PubMed ID: 19328514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein.
    Kaku Y; Noguchi A; Marsh GA; McEachern JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang LF
    J Virol Methods; 2009 Sep; 160(1-2):7-13. PubMed ID: 19433112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I interferon signaling protects mice from lethal henipavirus infection.
    Dhondt KP; Mathieu C; Chalons M; Reynaud JM; Vallve A; Raoul H; Horvat B
    J Infect Dis; 2013 Jan; 207(1):142-51. PubMed ID: 23089589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization and diagnostic evaluation of monoclonal antibody-based blocking ELISA formats for detection of neutralizing antibodies to Hendra virus in mammalian sera.
    Di Rubbo A; McNabb L; Klein R; White JR; Colling A; Dimitrov DS; Broder CC; Middleton D; Lunt RA
    J Virol Methods; 2019 Dec; 274():113731. PubMed ID: 31513861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.